EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01040832 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck Cancer

Interventions

DRUG: Cetuximab
DRUG: EMD 1201081

Sponsor

EMD Serono